Figure 3.
Progression-free survival in predefined patient subgroups. (A) refractory or relapsed after their first therapy; (B) ≤ 2 or ≥ 3 previous lines; (C) brentuximab vedotin naïve or brentuximab vedotin exposed.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.